Seventh indication approved for Humira
This article was originally published in Scrip
Executive Summary
Abbott's anti-inflammatory Humira (adalimumab), which is set to overtake Lipitor and Plavix to become the world's best-selling drug with sales of around $9 billion expected this year, has now received approval in the EU for its seventh indication, ulcerative colitis, following a CHMP positive opinion earlier this year (scripintelligence.com, 20 February 2012).